Adoptive therapy with CAR redirected T cells: The challenges in targeting solid tumors

Immunotherapy

Volumn 7, Issue 5, 2015, Pages 535-544

  Abken, Hinrich ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

adoptive cell therapy; cancer; CAR; chimeric antigen receptor; gene transfer; T cell

Indexed keywords

ACICLOVIR; CHIMERIC ANTIGEN RECEPTOR; CYTOKINE; GANCICLOVIR; PEMBROLIZUMAB; PLASMID DNA; TOCILIZUMAB; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CELL KILLING; CELL MIGRATION; CELL THERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; EX VIVO STUDY; GENE REPRESSION; GLIOMA; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LEUKEMIA; LYMPHOMA; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; SOLID TUMOR; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL; TRANSGENICS; GENETICS; IMMUNOLOGY; PATHOLOGY; TRANSPLANTATION;

HUMANS; LEUKEMIA; LYMPHOMA; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84931068909     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.15     Document Type: Review

References (75)

1. Eshhar Z. The T-body approach: redirecting T cells with antibody specificity. Handb. Exp. Pharmacol. 181, 329-342 (2008).
2. Elkord E, Dangoor A, Burt DJ et al. Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). Cancer Immunol. Immunother. 58, 1657-1667 (2009).
3. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18, 89-95 (1997).
4. Chmielewski M, Kopecky C, Hombach AA et al. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71, 5697-5706 (2011).
5. Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: Chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol. Rev. 257, 83-90 (2014).
6. Satta A, Mezzanzanica D, Turatti F et al. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. Future Oncol. 9, 527-539 (2013).
7. Chmielewski M, Hombach AA, Abken H. Antigen-specific T cell activation independently of the MHC: chimeric antigen receptor (CAR)-redirected T cells. Front. Immunol. 4, 71 (2013).
8. Muniappan A, Banapour B, Lebkowski J, Talib S. Ligand-mediated cytolysis of tumor cells: use of heregulin-zeta chimeras to redirect cytotoxic T lymphocytes. Cancer Gene Ther. 7, 128-134 (2000).
9. Kahlon KS1, Brown C, Cooper LJ et al. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 64, 9160-9166 (2004).
10. Tassev DV, Cheng M, Cheung NK. Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther. 19, 84-100 (2012).
11. Stewart-Jones G, Wadle A, Hombach A et al. Rational development of high-affinity T-cell receptor-like antibodies. Proc. Natl Acad. Sci. USA 106, 5784-5788 (2009).
12. Hombach A, Koch D, Sircar R et al. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in presence of soluble CEA. Gene Ther. 6, 300-304 (1999).
13. Louis CU, Savoldo B, Dotti G et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050-6056 (2011).
14. Chmielewski M, Rappl G, Hombach AA et al. T cells redirected by a CD3 chimeric antigen receptor can establish self-antigen specific tumour protection in long-term. Gene Ther. 20, 177-186 (2013).
15. Finney HM, Lawson AD, Bebbington CR et al. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161, 2791-2797 (1998).
16. Hombach AA, Abken H. Costimulation by chimeric antigen receptors revisited: the T cell antitumor response benefits from combined CD28-OX40 signalling. Int. J. Cancer 129, 2935-2944 (2011).
17. Hombach AA, Chmielewski M, Rappl G et al. Adoptive immunotherapy with redirected T cells produces CCR7- cells which are trapped in the periphery and benefit from combined CD28-OX40 costimulation. Hum. Gene Ther. 24, 259-269 (2013).
18. Chattopadhyay PK, Betts MR, Price DA et al. The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J. Leukoc. Biol. 85, 88-97 (2009).
19. Kershaw MH et al. A Phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-6115 (2006).
20. Brentjens RJ et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra138 (2013).
21. Porter DL, Levine BL, Kalos M et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
22. Singh H et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS ONE 8, e64138 (2013).
23. Park JR et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15, 825-833 (2007).
24. Zhao Y et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70, 9053-9061 (2010).
25. Krug C, Wiesinger M, Abken H et al. A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor. Cancer Immunol. Immunother. 63, 999-1008 (2014).
26. Maus MV, Haas AR, Beatty GL et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 1, 26-31 (2013).
27. Berger C, Jensen MC, Lansdorp PM et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118, 294-305 (2008).
28. Hinrichs CS, Borman ZA, Cassard L et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc. Natl Acad. Sci. USA 106, 17469-17474 (2009).
29. Klebanoff CA, Gattinoni L, Palmer DC et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 17, 5343-5352 (2011).
30. Kaneko S, Mastaglio S, Bondanza A et al. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 113, 1006-1015 (2009).
31. Pouw N, Treffers-Westerlaken E, Kraan J et al. Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells. Cancer Immunol. Immunother. 59, 921-931 (2010).
32. Suhoski MM et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol. Ther. 15, 981-988 (2007).
33. Lamers CH, Willemsen R, van Elzakker P et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117, 72-82 (2011).
34. Till BG, Jensen MC, Wang J et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112, 2261-2271 (2008).
35. Morgan RA, Yang JC, Kitano M et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843-851 (2010).
36. Brentjens R, Yeh R, Bernal Y et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a Phase I clinical trial. Mol. Ther. 18, 666-668 (2010).
37. Kochenderfer JN, Dudley ME, Feldman SA et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709-2720 (2012).
38. Grupp SA, Kalos M, Barrett D et al. Chimeric antigen receptor-modified T cells fo racute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518 (2013).
39. Lee DW, Gardner R, Porter DL et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188-195 (2014).
40. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46, 5276-5281 (1986).
41. Ciceri F, Bonini C, Stanghellini MT et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised Phase I-II study. Lancet Oncol. 10, 489-500 (2009).
42. Di Stasi A, Tey SK, Dotti G et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673-1683 (2011).
43. Introna M, Barbui AM, Bambacioni F et al. Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum. Gene Ther. 11, 611-620 (2000).
44. Philip B, Kokalaki E, Mekkaoui L et al. A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood 124, 1277-1287 (2014).
45. Wang X, Chang WC, Wong CW et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255-1263 (2011).
46. Kieback E, Charo J, Sommermeyer D et al. A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. Proc. Natl Acad. Sci. USA 105, 623-628 (2008).
47. Birkholz K, Hombach A, Krug C et al. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. Gene Ther. 16, 596-604 (2009).
48. Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).
49. Brentjens RJ, Rivire I, Park JH et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817-4828 (2011).
50. Kochenderfer JN, Wilson WH, Janik JE et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099-4102 (2010).
51. Lamers CH, Sleijfer S, Vulto AG et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20-22 (2006).
52. Chmielewski M, Hombach A, Heuser C et al. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J. Immunol. 173, 7647-1753 (2004).
53. Kakarla S, Chow KK, Mata M et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol. Ther. 21, 1611-1620 (2013).
54. Textor A, Listopad JJ, Wuhrmann LL et al. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ. Cancer Res. 74, 6796-6805 (2014).
55. Zhang B, Karrison T, Rowley DA et al. IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J. Clin. Invest. 118, 1398-1404 (2008).
56. Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822-1826 (2011).
57. Chmielewski M, Hahn O, Rappl G et al. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology 143, 1095-1107 (2012).
58. Kershaw MH, Wang G, Westwood JA et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum. Gene Ther. 13, 1971-1980 (2002).
59. Craddock JA, Lu A, Bear A et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. 33, 780-788 (2010).
60. Kandalaft LE, Facciabene A, Buckanovich RJ et al. Endothelin B receptor, a new target in cancer immune therapy. Clin. Cancer Res. 15, 4521-4528 (2009).
61. Bernhard H, Neudorfer J, Gebhard K et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol. Immunother. 57, 271-280 (2008).
62. Chinnasamy D, Yu Z, Theoret MR et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J. Clin. Invest. 120, 3953-3968 (2010).
63. Huang Y1, Yuan J, Righi E et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl Acad. Sci. USA 109, 17561-17566 (2012).
64. Katz SC, Burga RA, McCormack E et al. Phase I HepaticImmunotherapy for Metastases study of intra-arterial chimeric antigen receptor modified T cell therapy for CEA+ liver metastases.. Clin Cancer Res. pii, clincanres.1421.2014 (2015).
65. Pule MA, Savoldo B, Myers GD et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264-1270 (2008).
66. Disis ML. Immune regulation of cancer. J. Clin. Oncol. 28, 4531-4538 (2010).
67. Whiteside TL. Immune responses to malignancies. J. Allergy Clin. Immunol. 125, 272-283 (2010).
68. Kofler DM, Chmielewski M, Rappl G et al. CD28 costimulation impairs the efficacy of a redirected T cell anti-tumor attack in the presence of regulatory T cells which can be overcome by preventing lck activation. Mol. Ther. 19, 760-767 (2011).
69. John LB, Devaud C, Duong CP et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19, 5636-5646 (2013).
70. Koehler H, Kofler D, Hombach A et al. CD28 costimulation overcomes TGF-β mediated repression of proliferation of redirected human CD4+ and CD8+ T-cells in an anti-tumor cell attack. Cancer Res. 67, 2265-2273 (2007).
71. Kloss CC, Condomines M, Cartellieri M et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71-75 (2013).
72. Zhang L, Kerkar SP, Yu Z et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol. Ther. 19, 751-759 (2011).
73. Chmielewski M, Abken H. CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol. Immunother. 61, 1269-1277 (2012).
74. Gattinoni L, Lugli E, Ji Y et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290-1297 (2011).
75. Hawkins RE, Gilham DE, Debets R et al. Development of adoptive cell therapy for cancer: a clinical perspective. Hum. Gene Ther. 21, 665-672 (2010).